Background: Administering neoadjuvant chemotherapy gives opportunity to debulk tumor, improve surgical outcomes and treat micrometastatic disease. However, neoadjuvant chemotherapy has not had good success rate in achieving favorable outcomes in early-stage NSCLC, only 4% in prior studies. Nivolumab an anti-PD1 antibody has been shown to activate exist…
Keep reading with a 7-day free trial
Subscribe to Hematology Oncology Snippets to keep reading this post and get 7 days of free access to the full post archives.